Prospective Research Innovations Inc — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$704,026	27
2024	Research	$14,000	1
2021	Research	$17,457	2
2020	Research	$174,774	1
2019	Research	$60,451	2

Breakdown

Who paid Research payments · program years 2019–2025

Hoffmann-La Roche Limited $481,899 10 payments
Otsuka Pharmaceutical Development & Commercialization, Inc. $252,371 4 payments
BioXcel Therapeutics, Inc. $198,223 14 payments
Eli Lilly and Company $21,705 2 payments
Genentech, Inc. $16,200 2 payments
Allergan Inc. $311 1 payment

Studies the money was for Research payments · program years 2019–2025

Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity $481,899 10 payments
A Phase Iiib Multi-Center, Open-Label, Mirror-Image, Study in Adult Subjects With Schizophrenia Treated Prospectively for 6-Months With Abilify Mycite $235,225 3 payments
Bxcl501401 $198,223 14 payments
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone Or in Combination With Mirikizumab for the Treatment of Adult Patients With Moderately to Severely Active Ulcerative Colitis $21,705 2 payments
A Phase Iiib Multi-Center, Open-Label, Mirror-Image, Study in Adult Subjects With Schizophrenia Treated Prospectively for 6-Months With Abilify Mycite $17,146 1 payment
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM $16,200 2 payments
A 26-Week, Multicenter, Open-Label, Flexible-Dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia Or Bipolar I Disorder $311 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.